



Oncologists' views on **Biosimilars**




The FDA has recently approved a handful of biosimilars—biological medicines that contain a highly similar version of the active substance in an approved biologic product. And many more are in the development pipeline. Knowing how oncologists view biosimilars and how their perceptions are changing will be key to determining how treatment trends are likely to evolve over the next few years. Cardinal Health Specialty Solutions polled more than 200 oncologists to understand their views.


Most oncologists **ARE FAMILIAR** with biosimilars




TOP CONCERNS about biosimilars



Oncologists' views on the FDA approval process




Importance of **COST SAVINGS** when prescribing biosimilars



When it comes to treating **breast cancer**, **82%** of participating oncologists would be open to prescribing a biosimilar to treat both **adjuvant and metastatic patients.**

Biosimilars **approved for use** in United States*

* As of December 7, 2017



The research was fielded at live summit events hosted by Cardinal Health Specialty Solutions in 2016 and 2017. More than 200 oncologists from a mix of community and hospital-based practices participated in the research. To learn more, visit www.cardinalhealth.com/oncologyinsights.